Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute... Key PointsQuestionIs ubrogepant, an oral calcitonin gene–related peptide receptor antagonist, effective in the acute treatment of migraine? FindingsIn this randomized clinical trial that included 1686 participants, rates of pain freedom at 2 hours were significantly greater with ubrogepant 50 mg (21.8%) or 25 mg (20.7%) than with placebo (14.3%). Rates of freedom from the most bothersome migraine-associated symptom at 2 hours were significantly greater with the 50-mg (38.9%) dose but not the 25-mg (34.1%) dose vs placebo (27.4%). MeaningAcute treatment of migraine with ubrogepant compared with placebo led to significantly greater rates of pain freedom at 2 hours with both the 50-mg and 25-mg doses, and freedom from the most bothersome migraine-associated symptom at 2 hours only with the 50-mg dose. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine

Loading next page...
 
/lp/american-medical-association/effect-of-ubrogepant-vs-placebo-on-pain-and-the-most-bothersome-hENJTgPwtQ
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.16711
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionIs ubrogepant, an oral calcitonin gene–related peptide receptor antagonist, effective in the acute treatment of migraine? FindingsIn this randomized clinical trial that included 1686 participants, rates of pain freedom at 2 hours were significantly greater with ubrogepant 50 mg (21.8%) or 25 mg (20.7%) than with placebo (14.3%). Rates of freedom from the most bothersome migraine-associated symptom at 2 hours were significantly greater with the 50-mg (38.9%) dose but not the 25-mg (34.1%) dose vs placebo (27.4%). MeaningAcute treatment of migraine with ubrogepant compared with placebo led to significantly greater rates of pain freedom at 2 hours with both the 50-mg and 25-mg doses, and freedom from the most bothersome migraine-associated symptom at 2 hours only with the 50-mg dose.

Journal

JAMAAmerican Medical Association

Published: Nov 19, 2019

References